Bioinspired surface
for a better world.
Hospital-Acquired Infections account for
11 million global deaths every year
2 million cases in the US and 100,000 deaths of Americans per year
Biomimetic surface innovation
Our Patented Surface Engineering Technologies
Durable residual germicidal efficacy
Long-lasting germicidal Gemini surface technology, developed from NSF COVID-19 SBIR grant to prevent surface transmission of infectious diseases
Non-invasive dental bonding-debodning
Non-destructive wet bonding (etch-less) & on-demand de-bonding technology, developed and licensed to one of the leading dental devices manufacturers
Anti-biofilm & anti-infective catheters
Anti-biofouling & antimicrobial catheters, developed to prevent 11 million deaths each year from catheter-related bloodstream infections
Wet bonding
Non-toxic, biodegradable, strong surgical adhesives, developed from NIH Research grant to support sutures funded by NIH
Our biomimetic surface technology:
prevents adhesion of microorganisms
kills pathogens on contact
ACatechol’s non-etching dental bonding and on-demand de-bonding technology was licensed to Envisita Holdings (spun out of Danaher group).
ACatechol’s currently looking for strategic partners and investors for its antimicrobial & anti-biofouling surface technology to prevent Hospital-Acquired Infections and future epidemics.
Helping in the fight against COVID-19 with funding from the NSF.
ACatechol has received a National Science Foundation (NSF) COVID research grant to develop a germicidal coating technology that maintains effectiveness against microbes (including COVID-19 and secondary infections resulting from COVID-19 treatments) long after application.
NIH NIAID funding for anti-infective catheter technology.
ACatechol’s durable antibiofilm & anti-infective catheter project has received NIH funding to prevent central line associated bloodstream infections, responsible for 5 million annual global deaths.
NIH NIAMS funding for suture replacement technology.
ACatechol’s wet bonding project has received NIH funding to replace/aid suture to avoid painful and catastrophic revision surgery such as tendon-to-bone repair.
The
future
is now.
Contact us to discuss how we can revolutionize your product.